首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer 5-year disease-free and overall survival data

【24h】

Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer 5-year disease-free and overall survival data

机译：多柔比星/环磷酰胺联合多西他赛与序贯多西紫杉醇作为乳腺癌新患者的5年无病生存期和总体生存数据

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第2期|共1页
作者
Vriens B.; Aarts M.; Van Gastel S.; Van den Berkmortel F.; Smilde T.; Van Warmerdam L.; De Boer M.; Van Spronsen D. J.; Peer P.; Tjan-Heijnen V.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer 5-year disease-free and overall survival data [J] . Vriens B., Aarts M., Van Gastel S., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Suppla2期

机译：多柔比星/环磷酰胺联合多西他赛与序贯多西紫杉醇作为乳腺癌新患者的5年无病生存期和总体生存数据
2. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer [J] . VriensB.E.P.J., AartsM.J.B., DeVriesB., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2013,第15期

机译：阿霉素/环磷酰胺联合多西他赛与序贯多西他赛治疗乳腺癌新辅助治疗
3. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer. [J] . Schneeweiss A, Marme F, Ruiz A, Annals of oncology: official journal of the European Society for Medical Oncology . 2011,第3期

机译：阿霉素加培美曲塞联合多西紫杉醇与阿霉素加环磷酰胺联合多西紫杉醇联合多西紫杉醇作为早期乳腺癌的新辅助治疗的随机II期试验。
4. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019

机译：乳腺MRI辐射射清，用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
5. Early stage breast cancer and comorbidities: Their impact on breast cancer disease-free survival differences by ethnicity. [D] . Guerra, Sandra Lee. 2010

机译：早期乳腺癌和合并症：种族对乳腺癌无病生存率差异的影响。
6. Effects on quality of life anti-cancer responses breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer [O] . Leslie G Walker, Jennifer M Eremin, Mark M Aloysius, 2011

机译：新辅助多西紫杉醇对生活质量抗癌反应保乳手术和生存的影响：对新辅助阿霉素和环磷酰胺治疗的原发性乳腺癌患者每周多于三周服用多西他赛的随机研究
7. Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer [O] . Leslie G Walker, Jennifer M Eremin, Mark M Aloysius, 2011

机译：新辅助多西紫杉醇对生活质量，抗癌反应，保乳手术和生存的影响：原发性乳腺癌新辅助阿霉素和环磷酰胺治疗后每周和每三周服用多西他赛的随机研究

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号